Why Pfizer (PFE) Stock Is Down Today

NEW YORK (TheStreet) -- Pfizer  (PFE) dipped Tuesday after AstraZeneca  (AZN) detailed its plan to increase sales in the next decade as an independent company as Pfizer continues to pursue a takeover of the British company.

AstraZeneca said in a statement investors would benefit from a "strong and consistent revenue growth" as annual sales would increase to more than $45 billion by 2023. The company posted sales of $25.7 billion last year.

The British company again rebuffed Pfizer's takeover bid on Friday. Pfizer's third offer was for approximately $106 billion, but the No.8 drugmaker called this offer inadequate and said a buyout would disturb its new drugs in development.

Must Read: Warren Buffett's 10 Favorite Growth Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was down 1.54% to $29.50 at 3:01 p.m.

PFE Chart

PFE data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

NYSE Suspends Trading for Some Shares of Nasdaq-Listed Amazon, Alphabet

NYSE Suspends Trading for Some Shares of Nasdaq-Listed Amazon, Alphabet

Stocks Waver Amid a Rise in Bond Yields, Strong Earnings

Stocks Waver Amid a Rise in Bond Yields, Strong Earnings

Video: Jim Cramer Reveals Why He's Cautious on Stocks

Video: Jim Cramer Reveals Why He's Cautious on Stocks

Jim Cramer on Earnings: All Stories Aren't Equal

Jim Cramer on Earnings: All Stories Aren't Equal